Cogent Biosciences (COGT) Equity Ratio (2017 - 2026)

Cogent Biosciences' Equity Ratio history runs 10 years deep, the most recent figure standing at 0.67 for Q1 2026.

• In Q1 2026, Equity Ratio fell 12.79% year-over-year to 0.67; the TTM figure through Mar 2026 stood at 0.67 (down 12.79% YoY), while the FY2025 annual figure was 0.68, down 13.16% from the prior year.
• Equity Ratio was 0.67 for Q1 2026 at Cogent Biosciences, down from 0.68 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.91 in Q1 2022 to a low of 0.56 in Q2 2025.
• Historically, Equity Ratio has averaged 0.8 across 5 years, with a median of 0.85 in 2023.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio climbed 4.43% in 2024, then tumbled 35.01% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.85 in 2022, then retreated by 3.25% to 0.82 in 2023, then decreased by 4.97% to 0.78 in 2024, then fell by 13.16% to 0.68 in 2025, then dropped by 0.85% to 0.67 in 2026.
• The last three Equity Ratio figures came in at 0.67 (Q1 2026), 0.68 (Q4 2025), and 0.71 (Q3 2025), per Business Quant data.